Literature DB >> 28790484

Inherited Predisposition to Prostate Cancer: From Gene Discovery to Clinical Impact.

Kathleen A Cooney1.   

Abstract

Family history of prostate cancer is one of the three most important risk factors for the disease in addition to age and race. Yet despite the recognition of this significant heritable component, it has been challenging to identify the genes associated with prostate cancer predisposition. Initial approaches focused on the collection of multiplex prostate cancer families. However, despite more than 20 years of linkage studies, few genes have been identified that account for a significant number of hereditary prostate cancer families. Our research team studied a large number of families with linkage evidence to chromosome 17q21-22 and ultimately identified a recurrent mutation in the HOXB13 gene. The HOXB13 G84E mutation occurs on a common haplotype consistent with a founder allele and worldwide, this allele accounts for ~5% of hereditary prostate cancer families. Current research from us and others focuses on the use of whole exome sequencing to identify rare cancer-causing alleles in early-onset and/or metastatic prostate cancer cases. The recent recognition of both germline and somatic alterations in DNA repair genes is important because mutation carriers appear to have a significant likelihood of developing aggressive/metastatic cancer.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28790484      PMCID: PMC5525420     

Source DB:  PubMed          Journal:  Trans Am Clin Climatol Assoc        ISSN: 0065-7778


  30 in total

1.  Family History and Probability of Prostate Cancer, Differentiated by Risk Category: A Nationwide Population-Based Study.

Authors:  Ola Bratt; Linda Drevin; Olof Akre; Hans Garmo; Pär Stattin
Journal:  J Natl Cancer Inst       Date:  2016-07-10       Impact factor: 13.506

2.  Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement.

Authors:  Virginia A Moyer
Journal:  Ann Intern Med       Date:  2012-07-17       Impact factor: 25.391

3.  The HOXB13 G84E Mutation Is Associated with an Increased Risk for Prostate Cancer and Other Malignancies.

Authors:  Jennifer L Beebe-Dimmer; Matthew Hathcock; Cecilia Yee; Linda A Okoth; Charles M Ewing; William B Isaacs; Kathleen A Cooney; Stephen N Thibodeau
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-06-24       Impact factor: 4.254

4.  Cancer risks in BRCA2 mutation carriers.

Authors: 
Journal:  J Natl Cancer Inst       Date:  1999-08-04       Impact factor: 13.506

5.  A population-based assessment of germline HOXB13 G84E mutation and prostate cancer risk.

Authors:  Robert Karlsson; Markus Aly; Mark Clements; Lilly Zheng; Jan Adolfsson; Jianfeng Xu; Henrik Grönberg; Fredrik Wiklund
Journal:  Eur Urol       Date:  2012-07-20       Impact factor: 20.096

6.  Truncating BRCA1 mutations are uncommon in a cohort of hereditary prostate cancer families with evidence of linkage to 17q markers.

Authors:  Kimberly A Zuhlke; Jennifer J Madeoy; Jennifer Beebe-Dimmer; Kirsten A White; Angela Griffin; Ethan M Lange; Stephen B Gruber; Elaine A Ostrander; Kathleen A Cooney
Journal:  Clin Cancer Res       Date:  2004-09-15       Impact factor: 12.531

7.  Association analysis of 9,560 prostate cancer cases from the International Consortium of Prostate Cancer Genetics confirms the role of reported prostate cancer associated SNPs for familial disease.

Authors:  Craig C Teerlink; Stephen N Thibodeau; Shannon K McDonnell; Daniel J Schaid; Antje Rinckleb; Christiane Maier; Walther Vogel; Geraldine Cancel-Tassin; Christophe Egrot; Olivier Cussenot; William D Foulkes; Graham G Giles; John L Hopper; Gianluca Severi; Ros Eeles; Douglas Easton; Zsofia Kote-Jarai; Michelle Guy; Kathleen A Cooney; Anna M Ray; Kimberly A Zuhlke; Ethan M Lange; Liesel M Fitzgerald; Janet L Stanford; Elaine A Ostrander; Kathleen E Wiley; Sarah D Isaacs; Patrick C Walsh; William B Isaacs; Tiina Wahlfors; Teuvo Tammela; Johanna Schleutker; Fredrik Wiklund; Henrik Grönberg; Monica Emanuelsson; John Carpten; Joan Bailey-Wilson; Alice S Whittemore; Ingrid Oakley-Girvan; Chih-Lin Hsieh; William J Catalona; S Lilly Zheng; Guangfu Jin; Lingyi Lu; Jianfeng Xu; Nicola J Camp; Lisa A Cannon-Albright
Journal:  Hum Genet       Date:  2013-10-26       Impact factor: 4.132

8.  Whole exome sequencing in 75 high-risk families with validation and replication in independent case-control studies identifies TANGO2, OR5H14, and CHAD as new prostate cancer susceptibility genes.

Authors:  Danielle M Karyadi; Milan S Geybels; Eric Karlins; Brennan Decker; Laura McIntosh; Amy Hutchinson; Suzanne Kolb; Shannon K McDonnell; Belynda Hicks; Sumit Middha; Liesel M FitzGerald; Melissa S DeRycke; Meredith Yeager; Daniel J Schaid; Stephen J Chanock; Stephen N Thibodeau; Sonja I Berndt; Janet L Stanford; Elaine A Ostrander
Journal:  Oncotarget       Date:  2017-01-03

9.  Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.

Authors:  Colin C Pritchard; Joaquin Mateo; Michael F Walsh; Navonil De Sarkar; Wassim Abida; Himisha Beltran; Andrea Garofalo; Roman Gulati; Suzanne Carreira; Rosalind Eeles; Olivier Elemento; Mark A Rubin; Dan Robinson; Robert Lonigro; Maha Hussain; Arul Chinnaiyan; Jake Vinson; Julie Filipenko; Levi Garraway; Mary-Ellen Taplin; Saud AlDubayan; G Celine Han; Mallory Beightol; Colm Morrissey; Belinda Nghiem; Heather H Cheng; Bruce Montgomery; Tom Walsh; Silvia Casadei; Michael Berger; Liying Zhang; Ahmet Zehir; Joseph Vijai; Howard I Scher; Charles Sawyers; Nikolaus Schultz; Philip W Kantoff; David Solit; Mark Robson; Eliezer M Van Allen; Kenneth Offit; Johann de Bono; Peter S Nelson
Journal:  N Engl J Med       Date:  2016-07-06       Impact factor: 91.245

10.  HOXB13 G84E-related familial prostate cancers: a clinical, histologic, and molecular survey.

Authors:  Steven C Smith; Nallasivam Palanisamy; Kimberly A Zuhlke; Anna M Johnson; Javed Siddiqui; Arul M Chinnaiyan; Lakshmi P Kunju; Kathleen A Cooney; Scott A Tomlins
Journal:  Am J Surg Pathol       Date:  2014-05       Impact factor: 6.394

View more
  7 in total

1.  ACK1-AR and AR-HOXB13 signaling axes: epigenetic regulation of lethal prostate cancers.

Authors:  Eric H Kim; Dengfeng Cao; Nupam P Mahajan; Gerald L Andriole; Kiran Mahajan
Journal:  NAR Cancer       Date:  2020-08-27

2.  Association of a common genetic variant (insertion/deletion) in ACE gene with prostate cancer susceptibility in a Tunisian population.

Authors:  Rahma Said; Rim Jenni; Sami Boussetta; Feryel Ammous; Skander Zouari; Selim Zaghbib; Marouene Chakroun; Amine Derouiche; Mohamed Chebil; Slah Ouerhani
Journal:  J Clin Lab Anal       Date:  2021-11-19       Impact factor: 2.352

Review 3.  Homologous Recombination Deficiency in Ovarian, Breast, Colorectal, Pancreatic, Non-Small Cell Lung and Prostate Cancers, and the Mechanisms of Resistance to PARP Inhibitors.

Authors:  Negesse Mekonnen; Hobin Yang; Young Kee Shin
Journal:  Front Oncol       Date:  2022-06-17       Impact factor: 5.738

4.  Image-guided Raman spectroscopy navigation system to improve transperineal prostate cancer detection. Part 1: Raman spectroscopy fiber-optics system and in situ tissue characterization.

Authors:  Fabien Picot; Roozbeh Shams; Frédérick Dallaire; Guillaume Sheehy; Tran Trang; David Grajales; Mirela Birlea; Dominique Trudel; Cynthia Ménard; Samuel Kadoury; Frédéric Leblond
Journal:  J Biomed Opt       Date:  2022-09       Impact factor: 3.758

Review 5.  PARP Inhibitors in Advanced Prostate Cancer in Tumors with DNA Damage Signatures.

Authors:  Ciara S McNevin; Karen Cadoo; Anne-Marie Baird; Stephen P Finn; Ray McDermott
Journal:  Cancers (Basel)       Date:  2022-09-29       Impact factor: 6.575

Review 6.  Genetics and biology of prostate cancer.

Authors:  Guocan Wang; Di Zhao; Denise J Spring; Ronald A DePinho
Journal:  Genes Dev       Date:  2018-09-01       Impact factor: 11.361

7.  Clinicopathological characteristics of localized prostate cancer in younger men aged ≤ 50 years treated with radical prostatectomy in the PSA era: A systematic review and meta-analysis.

Authors:  Yu Zheng; Sharron X Lin; Shulin Wu; Douglas M Dahl; Michael L Blute; Wei-De Zhong; Xing Zhou; Chin-Lee Wu
Journal:  Cancer Med       Date:  2020-07-22       Impact factor: 4.452

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.